| Date | Title | Description | |
|---|---|---|---|
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
| 21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
| 21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Oct 2018 | Share capital increases and reductions | Private placement capital increase addressed to institutional investors, excluding preferential subscription rights | Download |
| 02 Oct 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2018 | Download |
| 24 Sep 2018 | Others on business performance and financial information | Updated information on business, financial position and risk factors | Download |
| 24 Sep 2018 | Share capital increases and reductions | Intention to raise gross proceeds by means of an offer addressed to institutional investors, excluding preferential subscription rights | Download |
| 26 Jul 2018 | Información sobre resultados | ROVI releases the 2018 first half results presentation | Download |